| 2025年中报 | 2024年年报 | 2024年中报 | 2023年年报 | 2023年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 代谢及消化系统疾病治疗领域核心产品(元) | 1,306,000,000.00 | 2,793,000,000.00 | 1,398,000,000.00 | 2,824,000,000.00 | 1,504,000,000.00 |
| 抗感染疾病治疗领域核心产品(元) | 1,656,000,000.00 | 3,126,000,000.00 | 1,453,000,000.00 | 4,340,000,000.00 | 3,318,000,000.00 |
| 抗肿瘤治疗领域核心产品(元) | 4,314,000,000.00 | 8,085,000,000.00 | 4,051,000,000.00 | 7,638,000,000.00 | 3,699,000,000.00 |
| 西药和原料药中间体等(元) | 607,000,000.00 | 1,106,000,000.00 | 560,000,000.00 | 1,271,000,000.00 | 654,000,000.00 |
| 血液系统疾病治疗领域核心产品(元) | 926,000,000.00 | 1,912,000,000.00 | 1,026,000,000.00 | 1,677,000,000.00 | 839,000,000.00 |
| 中枢神经系统疾病治疗领域核心产品(元) | 492,000,000.00 | 1,099,000,000.00 | 492,000,000.00 | 1,184,000,000.00 | 551,000,000.00 |
| 营业成本(元) | |||||
| 代谢及消化系统疾病治疗领域核心产品(元) | 361,000,000.00 | 693,000,000.00 | 341,000,000.00 | 639,000,000.00 | 326,000,000.00 |
| 抗感染疾病治疗领域核心产品(元) | 592,000,000.00 | 1,003,000,000.00 | 417,000,000.00 | 2,173,000,000.00 | 1,462,000,000.00 |
| 抗肿瘤治疗领域核心产品(元) | 968,000,000.00 | 1,716,000,000.00 | 853,000,000.00 | 1,566,000,000.00 | 757,000,000.00 |
| 西药和原料药中间体等(元) | 478,000,000.00 | 810,000,000.00 | 417,000,000.00 | 910,000,000.00 | 468,000,000.00 |
| 血液系统疾病治疗领域核心产品(元) | 425,000,000.00 | 1,185,000,000.00 | 645,000,000.00 | 1,042,000,000.00 | 507,000,000.00 |
| 中枢神经系统疾病治疗领域核心产品(元) | 71,000,000.00 | 159,000,000.00 | 53,000,000.00 | 107,000,000.00 | 50,000,000.00 |
| 毛利(元) | |||||
| 代谢及消化系统疾病治疗领域核心产品(元) | 945,000,000.00 | 2,100,000,000.00 | 1,057,000,000.00 | 2,185,000,000.00 | 1,178,000,000.00 |
| 抗感染疾病治疗领域核心产品(元) | 1,064,000,000.00 | 2,123,000,000.00 | 1,036,000,000.00 | 2,167,000,000.00 | 1,856,000,000.00 |
| 抗肿瘤治疗领域核心产品(元) | 3,346,000,000.00 | 6,369,000,000.00 | 3,198,000,000.00 | 6,072,000,000.00 | 2,942,000,000.00 |
| 西药和原料药中间体等(元) | 129,000,000.00 | 296,000,000.00 | 143,000,000.00 | 361,000,000.00 | 186,000,000.00 |
| 血液系统疾病治疗领域核心产品(元) | 501,000,000.00 | 727,000,000.00 | 381,000,000.00 | 635,000,000.00 | 332,000,000.00 |
| 中枢神经系统疾病治疗领域核心产品(元) | 421,000,000.00 | 940,000,000.00 | 439,000,000.00 | 1,077,000,000.00 | 501,000,000.00 |
| 毛利率(%) | |||||
| 代谢及消化系统疾病治疗领域核心产品(%) | 72.36 | 75.19 | 75.61 | 77.37 | 78.32 |
| 抗感染疾病治疗领域核心产品(%) | 64.25 | 67.91 | 71.30 | 49.93 | 55.94 |
| 抗肿瘤治疗领域核心产品(%) | 77.56 | 78.78 | 78.94 | 79.50 | 79.54 |
| 西药和原料药中间体等(%) | 21.25 | 26.76 | 25.54 | 28.40 | 28.44 |
| 血液系统疾病治疗领域核心产品(%) | 54.10 | 38.02 | 37.13 | 37.87 | 39.57 |
| 中枢神经系统疾病治疗领域核心产品(%) | 85.57 | 85.53 | 89.23 | 90.96 | 90.93 |
| 收入构成(%) | |||||
| 代谢及消化系统疾病治疗领域核心产品(%) | 14.04 | 15.41 | 15.57 | 14.91 | 14.24 |
| 抗感染疾病治疗领域核心产品(%) | 17.80 | 17.25 | 16.18 | 22.92 | 31.41 |
| 抗肿瘤治疗领域核心产品(%) | 46.38 | 44.62 | 45.11 | 40.34 | 35.01 |
| 西药和原料药中间体等(%) | 6.53 | 6.10 | 6.24 | 6.71 | 6.19 |
| 血液系统疾病治疗领域核心产品(%) | 9.96 | 10.55 | 11.43 | 8.86 | 7.94 |
| 中枢神经系统疾病治疗领域核心产品(%) | 5.29 | 6.06 | 5.48 | 6.25 | 5.22 |
| 毛利构成(%) | |||||
| 代谢及消化系统疾病治疗领域核心产品(%) | 14.75 | 16.73 | 16.90 | 17.48 | 16.84 |
| 抗感染疾病治疗领域核心产品(%) | 16.61 | 16.91 | 16.57 | 17.34 | 26.53 |
| 抗肿瘤治疗领域核心产品(%) | 52.23 | 50.73 | 51.14 | 48.59 | 42.06 |
| 西药和原料药中间体等(%) | 2.01 | 2.36 | 2.29 | 2.89 | 2.66 |
| 血液系统疾病治疗领域核心产品(%) | 7.82 | 5.79 | 6.09 | 5.08 | 4.75 |
| 中枢神经系统疾病治疗领域核心产品(%) | 6.57 | 7.49 | 7.02 | 8.62 | 7.16 |